Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656123 · ClinicalTrials.gov registry record · Phase 1
Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00656123 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 9 participants.
The verdict
NCT00656123, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and feasibility of vaccination with two irradiated allogeneic colorectal carcinoma cells administered with a GM-CSF producing bystander cell line in sequence with an immunomodulatory dose of Cyclophosphamide
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL Colon GVAX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-03 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00656123
The ClinicalTrials.gov registry entry for NCT00656123 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclophosphamide is the first listed.
NCT00656123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00656123 about?
NCT00656123 is a clinical study titled "Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer". The primary objective of this study is to evaluate the safety and feasibility of vaccination with two irradiated allogeneic colorectal carcinoma cells administered with a GM-CSF producing bystander cell line in sequence with an immunomodulatory dose of Cyclophosphamide
What is the current status of trial NCT00656123?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-03. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00656123?
The interventions under investigation include: cyclophosphamide (DRUG), Colon GVAX (BIOLOGICAL).
Who is sponsoring clinical trial NCT00656123?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.